



Figure S1. Consort participant flow diagram. Participants were enrolled between July 2012 and December 2015. The target sample size was based on the difference in overnight MST improvement between the placebo ($M \pm SD$: $1.5 \pm 20.6\%$; $n=11$) and eszopiclone ($20.5 \pm 23.4\%$; $n=10$) groups in our pilot study of schizophrenia, which gave a power of .90 with 28 participants [6]. The trial ended when the recruitment goals were met. SZ=schizophrenia; HC=healthy control.